Identification and Treatment of Tuberculosis in Pediatric Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: Case Series and Review of the Literature

This article was published in the following Dove Press journal: Infection and Drug Resistance

Background: Tuberculosis is a rare but life-threatening complication in patients who received hematopoietic stem cell transplantation. Early identification and intervention are essential to prevent severe complications.

Case Presentation: We report two pediatric patients who developed tuberculosis after receiving hematopoietic stem cell transplantation for thalassemia major among 330 recipients between January 2012 and August 2019. Patient A presented with pulmonary tuberculosis and patient B presented with lymph node tuberculosis mimicking post-transplantation lymphoproliferative disorder associated with Epstein–Barr virus reactivation. Patient B’s condition was deteriorated, and shortly after the initiation of anti-tuberculosis therapy, the patient was found to have disseminated pulmonary tuberculosis. Patient B was also found to have tuberculous granulomas, an uncommon manifestation of tuberculosis causing severe airway obstruction. Both patients developed critical respiratory failure and required mechanical ventilation; however, they recovered with almost full resolution of pulmonary lesions after multiple treatment adjustments.

Conclusion: Tuberculosis must be carefully evaluated in all pediatric patients that receive hematopoietic stem cell transplantation, regardless of the identification of other pathogens. Prophylactic tuberculosis therapy should be considered for high-risk pediatric hematopoietic stem cell transplantation recipients from tuberculosis-endemic regions.

Keywords: tuberculosis, hematopoietic stem cell transplantation, thalassemia, pediatric

Background

Recipients of hematopoietic stem cell transplantation (HSCT) are at a high risk of being infected with opportunistic pathogens, among which Mycobacterium tuberculosis (Mtb) is one of the most life-threatening pathogens.\(^1\) The incidence of tuberculosis (TB) ranges from 0.4% to approximately 6% in both HSCT as well as solid organ transplant recipients.\(^2\)–\(^6\) Typically, HSCT recipients in endemic regions are reported to have a significantly higher TB incidence than those in the non-endemic regions. Risk factors associated with TB in HSCT recipients, such as pre-transplant human leukocyte antigen (HLA) status, the presence of acute or chronic graft versus host disease (GVHD), the type of conditioning regimens, and the use of total body irradiation have been evaluated in previous studies.\(^5\)–\(^7\) However, most of these studies were based on small adult patient cohorts. Reports focusing on TB in pediatric HSCT recipients are limited.
The diagnosis of TB in HSCT recipients could be challenging because of the uncharacteristic symptom presentation, especially when Mtb co-exists with other pathogens. In this case report, we present the cases of two pediatric patients with thalassemia major (TM) who had undergone HSCT and developed TB with differing manifestations.

Case Presentation

Patient A

An 8-year-old girl with TM received granulocyte colony stimulating factor mobilized peripheral blood stem cells (PBSCs) from an unrelated human leukocyte antigen (HLA) 9/10 matched donor. The myeloablative conditioning regimen consisted of cyclophosphamide (CTX), busulfan (BU), fludarabine (FLU), and rabbit anti-thymocyte globulin (ATG). Graft-versus-host disease (GVHD) prophylaxis included cyclosporine (CSA), low dose methotrexate (MTX), and mycophenolate (MMF). Neutrophil engraftment was achieved by day 14 post-transplantation. The donor cell chimerism was >99%. Patient A was discharged on day 25 post-transplantation without severe complications.

The patient was readmitted for persistent high fever and cough on day 73 post-transplantation. Chest computed tomography (CT) scans suggested mild pneumonia without severe pulmonary lesions (Figure 1A). Despite the administration of broad-spectrum antibiotics and antifungal treatments, the patient developed severe respiratory distress requiring ventilatory support starting on day 82 post-transplantation. A bronchoscopy was performed at this time. Bronchoalveolar lavage (BAL) fluid tested positive for Mtb DNA ($2.79 \times 10^3$ copies/mL), cytomegalovirus (CMV) DNA ($2.65 \times 10^5$ copies/mL), and Epstein-Barr virus (EBV) DNA ($8.68 \times 10^6$ copies/mL) by real-time PCR analysis. Acid-fast bacilli (AFB) testing of the BAL fluid was negative. Thus, diagnoses of pulmonary TB, CMV, and EBV were considered. Ten days after the patient was hospitalized, TB treatment consisting of isoniazid, rifampin, and pyrazinamide, and antiviral therapy consisting of ganciclovir and intravenous immunoglobulin (IVIG) were initiated. The patient was removed from ventilator support 90 days post-transplantation.

Four days after the removal of the ventilator, the patient developed hematemesis and hemoptysis with continued high fever and persistent cough. A chest CT scan revealed the progression of pneumonia with massive pulmonary infiltrates (Figure 1B). The patient was again placed on a ventilator, and pneumorrhagia was observed during intubation. Streptomycin, linezolid, and levofloxacin were immediately added to the patient’s treatment regimen and antiviral treatment was changed to ganciclovir and foscarnet sodium. Empiric antibiotic and antifungal treatments were ongoing. The patient developed signs of hemophagocytic lymphohistiocytosis syndrome, including significant enlargement of the liver and spleen, pancytopenia, sudden elevated serum ferritin (18298 mmol/L), and delayed coagulation time. Methylprednisolone was added to the patient’s treatment regimen. The patient was removed from the ventilator support after showing progress. On day 110 post-transplantation, the patient was discharged and continued on a modified TB treatment regimen of oral isoniazid, rifampin, and pyrazinamide. Chest CT scans performed on day 326 post-transplantation revealed almost full resolution of pulmonary infiltrates (Figure 1C). The patient was continued on oral isoniazid, rifampin, and pyrazinamide treatment for a year before the discontinuation of anti-TB treatment.

Patient B

A 9-year-old boy received a haploidentical bone marrow (BM) and GCSF mobilized PBSC transplant from his biological father for TM treatment, and an HLA-mismatched umbilical cord blood (UCB) transplant from an unrelated donor 6 days later. The patient’s preparation regime consisted of CTX, BU, FLU, ATG, and thiotepa (TT). GVHD prophylaxis included post-transplant CTX, MMF, and tacrolimus (FK506). Neutrophil engraftment, delayed owing to UCB engraftment, was observed by day 40 post-transplantation with an absolute neutrophil count greater than $0.5 \times 10^9$ cells/L. On day 79 post-transplantation, the patient was treated for CMV reactivation with IVIG. Critical complications, including severe GVHDs, refractory pancytopenia, and life-threatening infections were not observed.

Patient B returned to the hospital with intermittent fever and enlargement of the lymph nodes of the neck and groin on day 89 post-transplantation. An ultrasound revealed that largest lymph node in the neck was 2.6 cm $\times$ 1.0 cm. Chest CT scans showed enlarged mediastinal and bronchial lymph nodes without significant pulmonary lesions (Figure 1D). PCR revealed plasma EBV-DNA ($1.08 \times 10^5$ copies/mL). Post-transplant lymphoproliferative disorder (PTLD) was suspected but could not be confirmed owing to the refusal of the patient’s parents to provide consent for a lymph node biopsy. A positron emission tomography-CT (PET-CT) scan revealed enlarged
lymph nodes with increased uptake of fluorodeoxyglucose in the neck, mediastinum, abdomen, and groin, supporting a diagnosis of PTLD. Consequently, the patient was administered foscarnet sodium, and rituximab once weekly for 3 weeks, a course of CTX, and a donor-derived EBV-specific cytotoxic T lymphocyte infusion between day 89 and 114 post-transplantation. The patient also received broad-spectrum antibiotics and prophylactic antifungals. The patient tested negative for EBV-DNA after receiving the first dose of rituximab.

Two weeks after the onset of symptoms, the patient had accelerated chest pain and breathing difficulties. On day 114 post-transplantation, biopsies of the lymph nodes in the neck were performed showing granulomas with caseous necrosis, indicating lymph node TB. On day 116 post-transplantation, AFB testing confirmed TB, and treatment with isoniazid, rifampin, pyrazinamide, levofloxacin, and linezolid was started immediately. The patient did not improve and developed severe chest pain, tachypnea, hypoxemia, and orthopnea within 5 days of the initiation of anti-TB treatment. Chest CT scans revealed bronchial stenosis in both bronchial tubes and worsening lymphadenectomy. A bronchoscopy revealed multiple granulomas severely restricting the primary bronchi (Figure 1G, H). AFB testing was negative; however, BAL fluid tested positive for Mtb by PCR.

Patient B developed type 1 respiratory failure after a week. Chest CT scans revealed massive infiltration, consolidation, and atelectasis of the right upper lobe of the lung, suggesting pulmonary TB (Figure 1E). The patient was then put on a ventilator after 3 days. Cryosurgery was performed via bronchoscopy to remove the granulomas and open the airways (Figure 1I). After a second cryosurgery, the patient showed gradual

Figure 1 Chest radiographs and bronchoscopy images of patients A and B during the course of treatment. Chest CT images of patient A revealed: (A) small nodular opacities in both lungs; (B) pulmonary infiltrates; and (C) dissolution of pulmonary lesions. Chest CT images of patient B revealed: (D) enlarged mediastinal and peribronchial lymph nodes; (E) massive infiltration, consolidation, and atelectasis of the right upper lobe of the lungs; and (F) a nearly full recovery and dissolution of pulmonary infiltrates. Bronchoscopy images of patient B on (G, H) day 127 post-HSCT and (I) day 137 post-HSCT showing tubercular granulomas obstructing the airways. (J) Bronchoscopy images showing tubercular granulomas within the respiratory tract mucosa that did not regrow following two cryosurgeries. CT, computed tomography; HSCT, hematopoietic stem cell transplantation.
improvement. On day 155 post-transplantation, a bronchoscopy showed clearance of granulomas from the bronchi (Figure 1J). On day 166 post-transplantation, chest CT scans revealed the dissolution of the majority of pulmonary infiltrates, and the patient was discharged (Figure 1F). He was prescribed oral rifapentine, isoniazid, pyrazinamide, and linezolid for a week, and then changed to rifapentine, isoniazid, and pyrazinamide treatment for the following 4 weeks. Pyrazinamide was discontinued after a month owing to elevated liver enzyme levels and as of the writing of this case report, the patient continues to receive oral rifapentine and isoniazid.

**Discussion and Conclusions**

TB is one of the most severe post-transplant complications. Twelve pediatric TB cases in HSCT recipients were reported in literature from 1990 to 2019 (Table 1).\(^2,6,7,9-12\) Mortality associated with pediatric post-HSCT TB may reach 50%.\(^10\) Between January 2012 and August 2019, our center reported only two pediatric TB cases out of 330 children who had undergone HSCT (0.60%). This is far lower than the number reported from other TB-endemic regions, potentially owing to China’s national bacilli Calmette-Guerin (BCG) vaccination program.\(^13,14\) In our center, nearly all patients that received HSCT were BCG vaccinated except a few patients with primary immunodeficiencies. In China, the incidence of pulmonary TB in children less than 15 years of age was 0.00244% between 2004 to 2015.\(^15\) Extrapulmonary TB was not included in this survey, and the incidence of TB may be much higher in pediatric HSCT recipients than that in the general pediatric population. Therefore, our patients were carefully screened for TB before HSCT and high-risk patients received prophylactic TB treatment.

In HSCT recipients, TB typically presents as a pulmonary infection, and TB affecting only the extrapulmonary sites is rare.\(^3,8,16-19\) TB in HSCT recipients can present atypically, and diagnoses may take weeks to confirm.\(^5,20\) TB diagnoses are complicated by the shortcomings of many testing methods. The gold standard for TB diagnoses is the isolation of Mtb by culture. However, this has a very high rate of false negatives. Most molecular methods involving nucleic acid amplification directly detect Mtb-DNA and can be used for the detection of genetic mutations associated with drug resistance. These methods generally have higher sensitivity and specificity compared to that of Mtb culture. However, the usefulness of molecular amplification methods has been limited because of the variable sensitivities, specificities, quality control issues, and costs.\(^21,22\) Genetic sequencing has high specificity, but low sensitivity. Interferon-γ (IFN-γ) assays have higher sensitivity than other methods, but a high rate of false positives.\(^14,23\) Radiological examinations often confuse TB with other pathogens. Complicating diagnoses in our TB patients were co-infections, such as those by CMV and EBV. Invasive testing such as bronchoscopy and tissue biopsies were required to confirm the presence of TB. Patient B had lymphoid TB and uncommon presentation that we initially believed to be PTLD owing to EBV infection.\(^24,25\) Unconventional, potentially invasive testing for TB should not be delayed in HSCT recipients.\(^1,26,27\)

Neither patient developed severe GVHD; however, GVHD increases the susceptibility to TB after HSCT, and the patients were receiving immunosuppressive therapies at the time of TB onset.\(^7\) HSCT recipients on immunosuppressive therapies are at an increased risk of acquiring TB.\(^28\) Patient B received UCB engraftment, which is often associated with delayed immune reconstitution and may result in higher morbidity and mortality in TB patients.\(^29,30\)

TB status should be evaluated carefully before HSCT. In our center, most children, except those with immunodeficiencies received the BCG vaccination. All potential HSCT recipients were screened for TB prior to transplantation using an IFN-γ release assay (IGRA) by ELISA, tubercular skin test (TST), and chest CT scans. A TST is considered positive when the reaction site is 10 mm in diameter or more. However, the sensitivity of TST is low (less than 50%). In addition, BCG vaccination can lead to a reaction at the TST site and cause false positive results in vaccinated children. Thus, we also performed an IGRA-ELISA assay as a screening test for TB. Suspected cases with positive results using TST or ELISA, and radiological findings suggestive of TB were assigned to an infectious disease specialist. To exclude TB, further examinations included an IGRA via QuantiFERON-TB Gold or T-SPOT assay. Less frequently, patients were assigned for PCR examination or high throughput sequencing for TB-DNA. Patients suspected of TB infections were administered prophylactic TB treatment approximately 3 months before and after HSCT. It has been suggested that prophylactic TB treatment should be considered in patients from endemic regions regardless of the TB status.\(^31\) The recommended prophylactic TB treatment is isoniazid or rifampicin alone or in combination.\(^20\) Long-term TB management is challenging owing to the development of resistant TB and hepatotoxicity associated with TB.
<table>
<thead>
<tr>
<th>No.</th>
<th>Authors, Year (Ref)</th>
<th>Country/Region</th>
<th>Age, Gender</th>
<th>Stem Cell Source</th>
<th>Primary Disease</th>
<th>TB Onset After HSCT</th>
<th>Diagnosis After Onset of Symptoms</th>
<th>TB location</th>
<th>GvHD Prophylaxis at TB Diagnosis</th>
<th>TB Regimens</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Present case 1</td>
<td>Mainland China</td>
<td>8 yr, F</td>
<td>HLA 9/10 unrelated donor</td>
<td>TM</td>
<td>73 days</td>
<td>80 days</td>
<td>Pulmonary</td>
<td>Cyclosporine, mycophenolate</td>
<td>H/R/Z for a week, H/R/Z/S/Lzd/Lfx for 5 weeks, then oral H/R/Z for a year</td>
<td>Alive</td>
</tr>
<tr>
<td>2</td>
<td>Present case 2</td>
<td>Mainland China</td>
<td>9 yr, M</td>
<td>Haplo-PBSC+ unrelated UCB</td>
<td>TM</td>
<td>89 days</td>
<td>14 days</td>
<td>Lymph nodes, then pulmonary dissemination</td>
<td>Tacrolimus</td>
<td>H/R/Z for a week then H/R/Z/Lzd/Lfx (R was switched to L after a week) for 7 weeks (S was given from the third week for 4 weeks); Continued with oral intake of H/L/Z for a month after discharged, then reduced to H/L due to elevated enzyme levels until the last follow up</td>
<td>Alive</td>
</tr>
<tr>
<td>3</td>
<td>Fan WC et al 2015</td>
<td>Taiwan</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3 cases identified among 39 children from 1997 to 2006</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Vercino et al 2012</td>
<td>Spain</td>
<td>8 yr, M</td>
<td>BMT</td>
<td>Bone marrow aplasia</td>
<td>50 days</td>
<td>1.5 months</td>
<td>Pulmonary/disseminated</td>
<td>Cyclosporine, mycophenolate</td>
<td>H/R/Z/M</td>
<td>Deceased</td>
</tr>
<tr>
<td>5</td>
<td>Biral et al 2012</td>
<td>Ukraine</td>
<td>10 yr, M</td>
<td>Alternative donor</td>
<td>ALL</td>
<td>2 months</td>
<td>&gt;4 months</td>
<td>Pulmonary</td>
<td>Cyclosporine, methylprednisolone</td>
<td>H/R/Z/M</td>
<td>Alive</td>
</tr>
<tr>
<td>6</td>
<td>Lee JW et al 2011</td>
<td>Taiwan</td>
<td>17 yr, M</td>
<td>BMT</td>
<td>ALL</td>
<td>2 months</td>
<td>3 months</td>
<td>Pulmonary</td>
<td>Cyclosporine</td>
<td>-</td>
<td>Deceased</td>
</tr>
<tr>
<td>7</td>
<td>Lee JW et al 2011</td>
<td>Taiwan</td>
<td>14 yr, F</td>
<td>PBSC</td>
<td>ALL</td>
<td>8 months</td>
<td>Suspected TB exposure to Patient 5 at 4 months after HSCT</td>
<td>Pulmonary</td>
<td>Cyclosporine, bedonethasone</td>
<td>H/R/Z/Lfx then R/Z/Lfx/Cs</td>
<td>Alive</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>No.</th>
<th>Authors, Year (Refs)</th>
<th>Country/Region</th>
<th>Age, Gender</th>
<th>Stem Cell Source</th>
<th>Primary Disease</th>
<th>TB Onset After HSCT</th>
<th>Diagnosis After Onset of Symptoms</th>
<th>TB location</th>
<th>GVHD Prophylaxis at TB Diagnosis</th>
<th>TB Regimens</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>George B et al 2005&lt;sup&gt;10&lt;/sup&gt;</td>
<td>India – 4 pediatric cases identified from 1986 to 2004</td>
<td>-</td>
<td>BMT</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>All patients were on steroids for GVHD</td>
<td>-</td>
<td>All patients responded well to anti-TB medications</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Chen CC et al 1999&lt;sup&gt;11&lt;/sup&gt;</td>
<td>Taiwan</td>
<td>10 yr, M</td>
<td>BMT</td>
<td>ALL</td>
<td>4 months</td>
<td>Pulmonary</td>
<td>Prednisolone, cyclosporine</td>
<td>H/R/Z</td>
<td>Deceased</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Ip MSM et al&lt;sup&gt;7&lt;/sup&gt;</td>
<td>Hong Kong</td>
<td>17 yr, M</td>
<td>Allogeneic BMT</td>
<td>MDS</td>
<td>120 days</td>
<td>-</td>
<td>Pulmonary</td>
<td>-</td>
<td>H/R/SZ for months, then H/R/S for 3 months, then H/R for another 3 months</td>
<td>Alive</td>
</tr>
<tr>
<td>11</td>
<td>Ip MSM et al&lt;sup&gt;7&lt;/sup&gt;</td>
<td>Hong Kong</td>
<td>17 yr, M</td>
<td>Allogeneic BMT</td>
<td>AML</td>
<td>550 days</td>
<td>-</td>
<td>Normal chest CT scan, positive lung Gallium scan</td>
<td>-</td>
<td>H/R/Z/O for 3 months, then H/R/O for 9 months</td>
<td>Alive</td>
</tr>
<tr>
<td>12</td>
<td>Ip MSM et al&lt;sup&gt;7&lt;/sup&gt;</td>
<td>Hong Kong</td>
<td>17 yr, F</td>
<td>MUD</td>
<td>CML</td>
<td>28 days</td>
<td>-</td>
<td>Pulmonary</td>
<td>-</td>
<td>Patient died before the diagnosis of TB</td>
<td>Deceased</td>
</tr>
</tbody>
</table>

**Abbreviations:** ALL, acute lymphoblastic leukemia; Allo, allogeneic; AML, acute myeloid leukemia; BMT, bone marrow transplantation; CML, chronic myeloid leukemia; Cs, cycloserine; CT, computed tomography; H, isoniazid; HSCT, hematopoietic stem cell transplantation; L, rifapentine; Lfx, levofloxacin; Ltd, linezolid; M, ethambutol; MDS, myelodysplastic syndrome; MUD, matched unrelated donor; O, ofloxacin; PBSC, peripheral blood stem cell; R, rifampin; S, streptomycin; TB, tuberculosis; TM, thalassemia major; UCB, umbilical cord blood; Z, pyrazinamide.
drugs and drug interactions.\textsuperscript{1} In this study, drug susceptibility test was not performed for resistant Mtb. However, the identification of drug resistance is important for guiding the appropriate treatment. Post HSCT prophylactic TB treatment is another important arm for preventing the occurrence of latent TB, but the decision of initiation and administration of the treatment is hard for clinicians owing to drug toxicity and a higher chance of developing chronic complications such as chronic GVHD.\textsuperscript{32,33} The choice of long-term TB prophylaxis also varies between transplant centers according to TB prevalence in different counties and regions. In our center, patients suspected of having TB by laboratory or radiological examinations during the pre-HSCT evaluation are prescribed with prophylactic isoniazid treatment for 3 months after transplantation. Patients are closely monitored for their liver, renal, and cardiac functions during the treatment for early identification of drug-related complications.

In conclusion, TB is a rare but potentially devastating complication in pediatric HSCT recipients. Post-HSCT TB is difficult to diagnose, particularly in patients with atypical presentation and co-infections. It is critical to carefully evaluate patients before ruling out TB. Prophylactic TB treatment may be necessary for pediatric HSCT recipients who were previously infected with TB or were in contact with persons with TB.

**Abbreviations**

AFB, acid-fast bacilli; BAL, bronchoalveolar lavage; CMV, cytomegalovirus; CT, computed tomography; EBV, Epstein–Barr virus; GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; IFN-\(\gamma\), interferon-\(\gamma\); Mtb, *Mycobacterium tuberculosis*; PCR, polymerase chain reaction; PTLD, post-transplant lympho-proliferative disorder; TB, tuberculosis; TM, thalassemia major; UCB, umbilical cord blood.

**Ethical Approval and Consent for Participate**

Written informed consents for both the publication of the images and case details had been obtained from parents of both patients. Ethical approvals were not required for case reports.

**Consent for Publication**

Written consent was obtained from the parents of both patients for the publication of this study.

**Acknowledgments**

We thank Prof Kuang-Yueh Chiang at the Hospital for Sick Children in Toronto for the consultation of both patients. Xiaodong Wang and Uet Yu are co-first authors for this study.

**Author Contributions**

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

**Funding**

This study was funded through Sanming Project of Medicine in Shenzhen (SZSM201512033) as part of the collaboration with the Hospital for Sick Children for clinical consultations.

**Disclosure**

The authors have no conflicts of interest to declare.

**References**